TAB3 — TAK1-Binding Protein 3
Introduction
TAB3 (TAK1-Binding Protein 3) is an essential adaptor protein in the [NF-κB](/mechanisms/nf-kb-signaling) and [MAPK signaling](/mechanisms/mapk-signaling) pathways. TAB3 partners with TAB2 to mediate the activation of TAK1 (MAP3K7) downstream of pro-inflammatory cytokines, toll-like receptors (TLRs), and growth factor receptors. Given the central role of chronic neuroinflammation in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), TAB3 has emerged as a critical regulator of neuroinflammatory processes and a potential therapeutic target.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TAK1-Binding Protein 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TAB3</td></tr>
<tr><td><strong>Full Name</strong></td><td>TAK1 Binding Protein 3</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>Xp11.23</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[85413](https://www.ncbi.nlm.nih.gov/gene/85413)</td></tr>
<tr><td><strong>OMIM</strong></td><td>300501</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169340</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9P0G2](https://www.uniprot.org/uniprot/Q9P0G2)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Neuroinflammation</td></tr>
</table>
</div>
Overview
TAB3 encodes TAK1-binding protein 3, an essential adaptor protein in the NF-κB and MAPK signaling pathways. TAB3 partners with TAB2 to mediate the activation of TAK1 (MAP3K7) downstream of TLRs, IL-1R, TNF receptors, and TGF-β receptors. Upon receptor activation, TAB3/TAB2 recruits TAK1 to the signaling complex, leading to TAK1 autophosphorylation and activation of downstream NF-κB and JNK pathways. TAB3 is critical for innate immune responses, inflammatory cytokine production, cell survival, and stress responses.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TAK1-Binding Protein 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TAB3</td></tr>
<tr><td><strong>Full Name</strong></td><td>TAK1 Binding Protein 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>Xp11.23</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[85413](https://www.ncbi.nlm.nih.gov/gene/85413)</td></tr>
<tr><td><strong>OMIM</strong></td><td>300501</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169340</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9P0G2](https://www.uniprot.org/uniprot/Q9P0G2)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Inflammation</td></tr>
</table>
</div>
Function
TAB3 encodes TAK1-binding protein 3, an essential adaptor protein in the [NF-κB](/entities/nf-kb) and MAPK signaling pathways. TAB3 partners with TAB2 to mediate the activation of TAK1 (MAP3K7) downstream of TLRs, IL-1R, TNF receptors, and TGF-β receptors. Upon receptor activation, TAB3/TAB2 recruits TAK1 to the signaling complex, leading to TAK1 autophosphorylation and activation of downstream NF-κB and JNK pathways. TAB3 is critical for innate immune responses, inflammatory cytokine production, cell survival, and stress responses.
Protein Structure and Function
Structural Features
TAB3 contains several key structural domains:
C-terminal ubiquitin-binding domain: Binds Lys63-linked polyubiquitin chains, essential for TAB3 recruitment to activated receptor complexes
Coiled-coil domain: Mediates homodimerization with TAB2 and interaction with TAK1
N-terminal domain: Contains the binding sites for TAK1The ubiquitin-binding function of TAB3 is critical — Lys63-linked ubiquitin chains on receptor-interacting proteins (e.g., RIP1, TRAF6) serve as platforms to recruit the TAB2/TAB3/TAK1 complex, enabling signal transduction.
Signal Transduction Mechanisms
TAB3 mediates signaling downstream of multiple receptor families:[@mumy2004]
- Cytokine receptors: IL-1R, IL-18R, TNF receptor superfamily
- TLRs: TLR2, TLR3, TLR4, TLR9
- TGF-β receptors: Type I and type II TGF-β receptors
- B-cell receptors (BCR): BCR engagement triggers TAK1 activation via TAB3
Expression
Tissue Distribution
TAB3 is widely expressed across multiple tissue types:
- Immune system: High expression in spleen, thymus, lymph nodes, peripheral blood leucocytes
- Brain: Expressed in [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and [microglia](/cell-types/microglia-neuroinflammation)
- Other organs: Heart, lung, liver, kidney
Brain Expression Pattern
In the central nervous system, TAB3 is expressed in:[@bjorklund2006]
- Microglia: High expression; central to neuroinflammatory responses
- Astrocytes: Moderate expression; involved in reactive astrogliosis
- Neurons: Lower but detectable expression; important for neuronal stress responses
- Oligodendrocytes: Expression detected in white matter regions
Expression is upregulated in response to:[@gera2019]
- Pro-inflammatory cytokines (IL-1β, TNF-α)
- Lipopolysaccharide (LPS)
- Aβ peptide exposure
- Mitochondrial toxins
Molecular Mechanisms in Neurodegeneration
TAK1/NF-κB Pathway Activation
TAK1 activation downstream of TAB3 triggers:[@inohara2005]
NF-κB activation: IKK phosphorylates IκBα, leading to NF-κB nuclear translocation
JNK activation: c-Jun N-terminal kinase activation
AP-1 activation: c-Fos/c-Jun heterodimer formation
MAPK cascades: ERK and p38 activationNeuroinflammation
TAK1/TAB3 signaling is a major driver of neuroinflammation:[@bhardwaj2015]
- Microglial activation: Chronic TAB3/TAK1 signaling promotes pro-inflammatory microglial phenotypes
- Cytokine production: IL-1β, TNF-α, IL-6 production
- Chemokine production: CCL2, CXCL10 recruitment of peripheral immune cells
- Reactive astrogliosis: Astrocyte activation and proliferation
Disease Associations
Alzheimer's Disease
TAK1/TAB3 signaling contributes to AD pathogenesis through multiple mechanisms:[@yang2017]
- Aβ-induced neuroinflammation: Aβ activates TAK1/TAB3 signaling in microglia, amplifying inflammatory responses
- Tau pathology: TAK1 signaling is enhanced in tauopathies
- Synaptic dysfunction: Chronic inflammation affects synaptic plasticity
- Neuronal loss: Pro-inflammatory signaling promotes excitotoxicity
Research has shown that:[@hu2018]
Aβ oligomers activate the TAK1/TAB3/NF-κB pathway in microglia
Blocking TAK1 reduces Aβ-induced inflammatory cytokine production
TAK1 inhibitors protect against synaptic dysfunction in AD modelsParkinson's Disease
TAK1/TAB3 signaling is implicated in PD pathogenesis:[@song2016]
- MPTP toxicity: TAK1 activation in response to MPTP and other mitochondrial toxins
- Alpha-synuclein pathology: Activated TAK1 in Lewy body-bearing neurons
- Microglial activation: Chronic neuroinflammation in PD substantia nigra
- Dopaminergic neuron vulnerability: TAK1-mediated inflammatory responses
Amyotrophic Lateral Sclerosis
TAK1 contributes to ALS progression:[@chen2014]
- SOD1 mutations: Mutant SOD1 activates TAK1/TAB3 signaling
- Non-cell autonomous toxicity: Microglial TAK1 signaling promotes motor neuron degeneration
- Glial contribution: Astrocyte and microglial TAK1 drives inflammation[@liu2016]
Other Neurodegenerative Conditions
- Multiple System Atrophy: Enhanced TAK1 signaling in oligodendrocytes
- Traumatic Brain Injury: TAK1 activation mediates secondary injury[@xu2018]
- Ischemic Stroke: TAK1 contributes to ischemic damage; TAK1 deficiency is protective[@wu2019]
- Down Syndrome: Elevated TAK1 signaling contributes to neurodevelopmental issues[@zhang2018]
Therapeutic Implications
TAK1 Inhibitors
Several TAK1 inhibitors have been explored for neurodegenerative diseases:[@yuan2019]
| Compound | Mechanism | Stage | Reference |
|---------|-----------|-------|-----------|
| (5Z)-7-Oxozeaenol | Irreversible TAK1 inhibition | Preclinical | -- |
| LL-Z1640-2 | Reversible TAK1 inhibition | Preclinical | -- |
| NG25 | TAK1/NIK inhibitor | Preclinical | -- |
Targeting Downstream Pathways
- NF-κB inhibitors: Block chronic NF-κB activation
- JNK inhibitors: Prevent JNK-mediated apoptosis
- p38 inhibitors: Reduce cytokine production
Natural Compounds
- Curcumin: Inhibits TAK1 activation
- Resveratrol: Modulates NF-κB signaling
- Omega-3 fatty acids: Anti-inflammatory effects
Interactions
Protein-Protein Interactions
TAB3 interacts with:
- TAK1 (MAP3K7): Primary interaction partner; TAB3 recruits TAK1 to activated receptors
- TAB2: Forms heterodimer; cooperative function
- TRAF2/TRAF6: Ubiquitin ligases that generate signaling platforms
- RIP1 (TNFRSF1A): Kinase downstream of TNF receptors
- NEMO (IKBKG): Regulatory subunit of IKK complex
- [TAK1](/genes/map3k7) — MAP3K7, the kinase partner
- [TAB2](/genes/tab2) — TAB2, related adaptor protein
- [NF-κB](/mechanisms/nf-kb-signaling) — Downstream pathway
- [MAPK Signaling](/mechanisms/mapk-signaling) — Downstream pathway
Animal Models
- TAB3 knockout mice: Embryonic lethal; essential for development
- Conditional knockout: Used to study glial TAK1 function
- Transgenic mice: TAK1 activation in neurons or glia
Research Directions
- Biomarkers: TAB3 expression as a marker of neuroinflammation
- Genetic variants: TAB3 polymorphisms in neurodegenerative disease risk
- Combination therapies: TAK1 inhibitors with other agents
Key Publications
[12872135](https://pubmed.ncbi.nlm.nih.gov/12872135/): TAB proteins in NF-κB signaling. Nat Rev Immunol, 2003.
[16254228](https://pubmed.ncbi.nlm.nih.com/16254228/): TAB3 structure and function. Mol Cell, 2005.
[18669857](https://pubmed.ncbi.nlm.nih.gov/18669857/): NF-κB in neurodegeneration. Brain, 2008.
[25363767](https://pubmed.ncbi.nlm.nih.gov/25363767/): Neuroinflammation in AD. Nat Neurosci, 2014.
[28642202](https://pubmed.ncbi.nlm.nih.gov/28642202/): Inflammation in neurodegeneration. Nat Rev Neurosci, 2017.
[33277862](https://pubmed.ncbi.nlm.nih.gov/33277862/): Therapeutic targeting. Brain, 2020.See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [NF-κB Signaling](/mechanisms/nf-kb-signaling-neurodegeneration)
- [TAK1 Signaling](/mechanisms/tak1-map3k7-signaling)
- [Microglia](/cell-types/microglia)
Overview
Tab3 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Tab3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
<references>
- Chen ZJ, et al. (2003). TAB proteins in NF-κB activation. Nat Rev Immunol 3: 415-428.
- Kanayama A, et al. (2004). TAB2 and TAB3 in NF-κB activation. Mol Cell 15: 535-548.
- Goldman T, et al. (2015). Neuroinflammation in AD. Nat Neurosci 18: 1746-1755.
</references>